Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

被引：31

作者：

Pasquini, Marcelo C. ^{[1
]}

Zhang, Mei-Jie ^{[1
,2
]}

Medeiros, Bruno C. ^{[3
]}

Armand, Philippe ^{[4
]}

Hui, Zhen-Huan ^{[1
]}

Nishihori, Taiga ^{[5
]}

Aljurf, Mahmoud D. ^{[6
]}

Akpek, Goerguen ^{[7
]}

Cahn, Jean-Yves ^{[8
]}

Cairo, Mitchell S. ^{[9
]}

Cerny, Jan ^{[10
]}

Copelan, Edward A. ^{[11
]}

Deol, Abhinav ^{[12
]}

Freytes, Cesar O. ^{[13
,14
]}

Gale, Robert Peter ^{[15
]}

Ganguly, Siddhartha ^{[16
]}

George, Biju ^{[17
]}

Gupta, Vikas ^{[18
]}

Hale, Gregory A. ^{[19
]}

Kamble, Rammurti T. ^{[20
]}

Klumpp, Thomas R. ^{[21
]}

Lazarus, Hillard M. ^{[22
]}

Luger, Selina M. ^{[23
]}

Liesveld, Jane L. ^{[24
]}

Litzow, Mark R. ^{[25
]}

Marks, David I. ^{[26
]}

Martino, Rodrigo ^{[27
]}

Norkin, Maxim ^{[28
]}

Olsson, Richard F. ^{[29
,30
]}

Oran, Betul ^{[31
]}

Pawarode, Attaphol ^{[32
]}

Pulsipher, Michael A. ^{[33
]}

Ramanathan, Muthalagu ^{[10
]}

Reshef, Ran ^{[23
]}

Saad, Ayman A. ^{[34
]}

Saber, Wael ^{[1
]}

Savani, Bipin N. ^{[35
]}

Schouten, Harry C. ^{[36
]}

Ringden, Olle ^{[29
,37
]}

Tallman, Martin S. ^{[38
]}

Uy, Geoffrey L. ^{[39
]}

Wood, William A., Jr. ^{[40
]}

Wirk, Baldeep ^{[41
]}

Perez, Waleska S. ^{[1
]}

Batiwalla, Minoo ^{[42
]}

Weisdorf, Daniel J. ^{[43
]}

机构：

[1] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA

[2] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA

[3] Stanford Univ, Sch Med, Dept Hematol, Stanford, CA 94305 USA

[4] Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA

[6] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia

[7] Banner MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Gilbert, AZ USA

[8] Univ Hosp, Dept Hematol, Grenoble, France

[9] New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA

[10] UMass Mem Med Ctr, Dept Med, Worcester, MA USA

[11] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[12] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[13] S Texas Vet Hlth Care Syst, Div Hematol & Oncol, San Antonio, TX USA

[14] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[15] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England

[16] Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA

[17] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India

[18] Univ Hlth Network, Princess Margaret Canc Ctr, Blood & Marrow Transplant Program, Toronto, ON, Canada

[19] Univ S Florida, All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL 33701 USA

[20] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA

[21] Thomas Jefferson Univ Hosp, Dept Med Oncol, Philadelphia, PA 19107 USA

[22] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA

[23] Univ Penn, Med Ctr, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA

[24] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA

[25] Mayo Clin, Div Hematol & Transplant Ctr, Rochester, MN USA

[26] Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England

[27] Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain

[28] Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA

[29] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden

[30] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden

[31] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA

[32] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[33] Univ So Calif, Keck Sch Med, Childrens Hosp Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA

[34] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA

[35] Vanderbilt Univ, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA

[36] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands

[37] Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden

[38] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[39] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[40] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA

[41] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA

[42] NHLBI, NIH, Hematol Branch, Bldg 10, Bethesda, MD 20892 USA

[43] Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2016年 / 22卷 / 02期

关键词：

Monosomal karyotype; Acute myeloid leukemia; Myelodysplastic syndrome; Allogeneic transplantation; LEUKEMIA WORKING PARTY; REDUCED-INTENSITY; PROGNOSTIC VALUE; SCORING SYSTEM; ALLOGENEIC TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; CONDITIONING REGIMEN; INTERNATIONAL BLOOD; IMPACT; CYTOGENETICS;

D O I：

10.1016/j.bbmt.2015.08.024

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.

引用

页码：248 / 257

页数：10

共 43 条

[1] Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity [J].

Ahn, Hee Kyung ;

Jang, Jun Ho ;

Kim, Kihyun ;

Kim, Hee-Jin ;

Kim, Sun-Hee ;

Jung, Chul Won ;

Kim, Dong Hwan .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) :37-41

[2]

[Anonymous], LEUK RES

[3]

[Anonymous], CLIN TRANSPLANTS 201

[4] Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].

Aoudjhane, M ;

Labopin, M ;

Gorin, NC ;

Shimoni, A ;

Ruutu, T ;

Kolb, HJ ;

Frassoni, F ;

Boiron, JM ;

Yin, JL ;

Finke, J ;

Shouten, H ;

Blaise, D ;

Falda, M ;

Fauser, AA ;

Esteve, J ;

Polge, E ;

Slavin, S ;

Niederwieser, D ;

Nagler, A ;

Rocha, V .

LEUKEMIA, 2005, 19 (12) :2304-2312

[5] Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study [J].

Armand, Philippe ;

Kim, Haesook T. ;

Zhang, Mei-Jie ;

Perez, Waleska S. ;

Dal Cin, Paola S. ;

Klumpp, Thomas R. ;

Waller, Edmund K. ;

Litzow, Mark R. ;

Liesveld, Jane L. ;

Lazarus, Hillard M. ;

Artz, Andrew S. ;

Gupta, Vikas ;

Savani, Bipin N. ;

McCarthy, Philip L. ;

Cahn, Jean-Yves ;

Schouten, Harry C. ;

Finke, Juergen ;

Ball, Edward D. ;

Aljurf, Mahmoud D. ;

Cutler, Corey S. ;

Rowe, Jacob M. ;

Antin, Joseph H. ;

Isola, Luis M. ;

Di Bartolomeo, Paolo ;

Camitta, Bruce M. ;

Miller, Alan M. ;

Cairo, Mitchell S. ;

Stockerl-Goldstein, Keith ;

Sierra, Jorge ;

Savoie, M. Lynn ;

Halter, Joerg ;

Stiff, Patrick J. ;

Nabhan, Chadi ;

Jakubowski, Ann A. ;

Bunjes, Donald W. ;

Petersdorf, Effie W. ;

Devine, Steven M. ;

Maziarz, Richard I. ;

Bornhauser, Martin ;

Lewis, Victor A. ;

Marks, David I. ;

Bredeson, Christopher N. ;

Soiffer, Robert J. ;

Weisdorf, Daniel J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) :280-288

[6] Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia [J].

Boudry-Labis, Elise ;

Roche-Lestienne, Catherine ;

Nibourel, Olivier ;

Boissel, Nicolas ;

Terre, Christine ;

Perot, Christine ;

Eclache, Virginie ;

Gachard, Nathalie ;

Tigaud, Isabelle ;

Plessis, Ghislaine ;

Cuccuini, Wendy ;

Geffroy, Sandrine ;

Villenet, Celine ;

Figeac, Martin ;

Lepretre, Frederic ;

Renneville, Aline ;

Cheok, Meyling ;

Soulier, Jean ;

Dombret, Herve ;

Preudhomme, Claude .

AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) :306-311

[7] Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype [J].

Breems, Dimitri A. ;

Van Putten, Wim L. J. ;

De Greef, Georgine E. ;

Van Zelderen-Bhola, Shama L. ;

Gerssen-Schoorl, Klasien B. J. ;

Mellink, Clemens H. M. ;

Nieuwint, Aggie ;

Jotterand, Martine ;

Hagemeijer, Anne ;

Beverloo, H. Berna ;

Lowenberg, Bob .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4791-4797

[8] The impact of abn(17p) and monosomy-5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia [J].

Breems, Dimitri A. ;

Van Putten, Wim L. J. ;

Lowenberg, Bob .

BLOOD, 2013, 121 (15) :3056-3057

[9] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[10] Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT [J].

Chevallier, P. ;

Labopin, M. ;

Milpied, N. ;

Cornelissen, J. J. ;

Blaise, D. ;

Petersen, E. ;

Sandstedt, A. ;

Goker, H. ;

Socie, G. ;

Rocha, V. ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2012, 47 (11) :1442-1447

← 1 2 3 4 5 →